Amplify Weight Loss Drug & Treatment ETF
Not enough financial coverage to compute a composite score for THNR. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companyamplifyetfs.com/thnr
THNR provides access to global companies expected to economically benefit from weight loss drug development. THNR seeks investment results that generally correspond to the performance (before fees and expenses) of the VettaFi Weight Loss Drug & Treatment Index.
- IPO
- 2024
- HQ
- Lisle, IL, US
Price Chart
Valuation
- Market Cap
- $3.22M
- Div Yield
- 1.67%
Performance & Tape
- 52W High
- $27.28
- 52W Low
- $21.47
- 50D MA
- $24.45
- 200D MA
- $24.56
- Beta
- 0.41
- Avg Volume
- 1.15K
Get TickerSpark's AI analysis on THNR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our THNR Coverage
We haven't published any research on THNR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THNR Report →